• Je něco špatně v tomto záznamu ?

Aristolochic acid and its effect on different cancers in uro-oncology

K. Rebhan, IE. Ertl, SF. Shariat, AP. Grollman, T. Rosenquist,

. 2020 ; 30 (5) : 689-695. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20027876

PURPOSE OF REVIEW: To acquaint urologists with aristolochic acid nephropathy, an iatrogenic disease that poses a distinct threat to global public health. In China alone, 100 million people may currently be at risk. We illustrate the power of molecular epidemiology in establishing the cause of this disease. RECENT FINDINGS: Molecular epidemiologic approaches and novel mechanistic information established a causative linkage between exposure to aristolochic acid and urothelial carcinomas of the bladder and upper urinary tract. Noninvasive tests are available that detect urothelial cancers through the genetic analysis of urinary DNA. Combined with cytology, some of these tests can detect 95% of patients at risk of developing bladder and/or upper urothelial tract cancer. Robust biomarkers, including DNA-adduct and mutational signature analysis, unequivocally identify aristolochic acid-induced tumours. The high mutational load associated with aristolochic acid-induced tumours renders them candidates for immune-checkpoint therapy. SUMMARY: Guided by recent developments that facilitate early detection of urothelial cancers, the morbidity and mortality associated with aristolochic acid-induced bladder and upper tract urothelial carcinomas may be substantially reduced. The molecular epidemiology tools that define aristolochic acid-induced tumours may be applicable to other studies assessing potential environmental carcinogens.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20027876
003      
CZ-PrNML
005      
20210114152532.0
007      
ta
008      
210105s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MOU.0000000000000806 $2 doi
035    __
$a (PubMed)32701724
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rebhan, Katharina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Austria.
245    10
$a Aristolochic acid and its effect on different cancers in uro-oncology / $c K. Rebhan, IE. Ertl, SF. Shariat, AP. Grollman, T. Rosenquist,
520    9_
$a PURPOSE OF REVIEW: To acquaint urologists with aristolochic acid nephropathy, an iatrogenic disease that poses a distinct threat to global public health. In China alone, 100 million people may currently be at risk. We illustrate the power of molecular epidemiology in establishing the cause of this disease. RECENT FINDINGS: Molecular epidemiologic approaches and novel mechanistic information established a causative linkage between exposure to aristolochic acid and urothelial carcinomas of the bladder and upper urinary tract. Noninvasive tests are available that detect urothelial cancers through the genetic analysis of urinary DNA. Combined with cytology, some of these tests can detect 95% of patients at risk of developing bladder and/or upper urothelial tract cancer. Robust biomarkers, including DNA-adduct and mutational signature analysis, unequivocally identify aristolochic acid-induced tumours. The high mutational load associated with aristolochic acid-induced tumours renders them candidates for immune-checkpoint therapy. SUMMARY: Guided by recent developments that facilitate early detection of urothelial cancers, the morbidity and mortality associated with aristolochic acid-induced bladder and upper tract urothelial carcinomas may be substantially reduced. The molecular epidemiology tools that define aristolochic acid-induced tumours may be applicable to other studies assessing potential environmental carcinogens.
650    _2
$a kyseliny aristolochové $x toxicita $7 D034341
650    _2
$a balkánská nefropatie $x chemicky indukované $7 D001449
650    _2
$a karcinogeny $7 D002273
650    _2
$a adukty DNA $x genetika $x metabolismus $7 D018736
650    _2
$a léky rostlinné čínské $x škodlivé účinky $7 D004365
650    _2
$a lidé $7 D006801
650    _2
$a nádory močového měchýře $x chemicky indukované $7 D001749
650    _2
$a urologické nádory $x chemicky indukované $7 D014571
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ertl, Iris E $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Austria.
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Austria. Department of Urology, Weill Cornell Medical College, New York, New York. Department of Urology, University of Texas Southwestern, Dallas, Texas, USA. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.
700    1_
$a Grollman, Arthur P $u Department of Pharmacological Sciences. Department of Medicine, Stony Brook University, Stony Brook, New York, USA.
700    1_
$a Rosenquist, Thomas $u Department of Pharmacological Sciences.
773    0_
$w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 30, č. 5 (2020), s. 689-695
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32701724 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114152530 $b ABA008
999    __
$a ok $b bmc $g 1608211 $s 1119056
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 30 $c 5 $d 689-695 $e - $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...